Quote:

---

I didn't see any reference to possible Alzheimers efficacy in your summary, likely because it's just a theoretical application at this point. But I have seen something called "Pepinemab" being developed to potentially treat Alzheimer’s, so -

Do you know if Leronlimab would have a similar MOA as Pepinemab? Or is Pepinemab better suited to tackle Alzheimer’s than Leronlimab?

---

Pepinemab downregulates SEMA4D an activator of NF-kb an inflammatory cytokine. Leronlimab also downregulates NF-kb but also a host of other inflammatory cytokines.

A phase 2 trial was done for Pepinemab in Huntington's disease. The results showed improved cognition but it failed to show statistical significance in disease progression. Which may be a result of attacking part of the problem but still leaving an inflammatory response in place. Leronlimab has a much broader reach when attenuating inflammation.